AbbVie (NYSE:ABBV) has filed a lawsuit against the U.S. Department of Health and Human Services over the inclusion of Botox in Medicare price negotiations. The company argues that Botox should be ...

AbbVie has sued the Department of Health and Human Services (HHS), challenging the agency’s decision to select its ...

AbbVie Inc. is challenging the Trump administration’s decision to select its Botox drug for a government program that slashes ...

In response to last month’s list of the 15 drugs chosen by the Centers for Medicare & Medicaid Services (CMS) for upcoming price cuts under the Inflation Reduction Act (IRA), AbbVie is the late | The ...

AbbVie sues HHS over Botox Medicare pricing, challenging CMS authority under the Inflation Reduction Act and drug price negotiation rules.

AbbVie contends that Botox should have been excluded from the IRA drug price negotiation program because it is a plasma-derived product.

Fifteen prescription medications will be the focus of federal price negotiations that could lower prices for Medicare patients.

Botox first became a household name for its ability to turn back the clock on facial aging. However, if you are considering Botox for cosmetic reasons and expecting Medicare coverage, you’ll be ...

Botox vs fillers compared. Understand cosmetic injectables, treatment differences, and what to expect from today's anti aging ...